The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy.

Asset-led transaction to add intellectual property and development materials related principally to the SSR-W advanced reactor and WATSS spent nuclear fuel recycling technologies.

DALLAS, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company") today announced that its merger partner, Nuclea Energy, Inc. ("Nuclea"), an advanced nuclear technology company headquartered in Mississauga, Ontario, developing the Morpheus microreactor, a lead-cooled, factory-built micro-modular reactor, through its wholly owned subsidiary, Nuclea Energy Canada Inc. ("Nuclea Canada"), has entered into a definitive agreement with Moltex Energy Limited ("Moltex") – currently in administration – and its joint administrators to acquire advanced nuclear technology assets across its molten salt reactor and nuclear fuel recycling portfolio.

Under the agreement, Nuclea Energy Canada will satisfy the purchase price entirely in cash, exclusive of any applicable value-added tax and subject to a downward adjustment for certain defined external debts.

Transaction Terms and Closing Conditions

The transaction is being conducted as a sale by Moltex while it is in administration. The assets are therefore being acquired on an "as is" basis, with limited warranties from the seller and administrators.

Completion of the transaction remains subject to the satisfaction or waiver of closing conditions set forth in the definitive agreement, including applicable review under the United Kingdom’s National Security and Investment Act. Nuclea has already obtained certain required Canadian governmental and program-related consents, including from the Strategic Innovation Fund and the Atlantic Canada Opportunities Agency.

The agreement provides for a longstop date three months following signing, unless extended by written agreement of the parties. There can be no assurance that the closing conditions will be satisfied or waived, that all contemplated assets and rights will be successfully transferred, or that the transaction will be completed on the terms or within the timeframe currently contemplated.